Literature DB >> 34248088

Finding Importance for Universal Screening of Familial Hypercholesterolemia.

Shinji Yokoyama1.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 34248088      PMCID： PMC9174091          DOI： 10.5551/jat.ED183

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN： 1340-3478            Impact factor:   4.394


× No keyword cloud information.
  9 in total

1.  Impact of statin treatment on the clinical fate of heterozygous familial hypercholesterolemia.

Authors:  Mariko Harada-Shiba; Takako Sugisawa; Hisashi Makino; Mitsuru Abe; Motoo Tsushima; Yasunao Yoshimasa; Takahiro Yamashita; Yoshihiro Miyamoto; Akira Yamamoto; Hitonobu Tomoike; Shinji Yokoyama
Journal:  J Atheroscler Thromb       Date:  2010-06-04       Impact factor: 4.928

2.  Development of coronary heart disease in familial hypercholesterolemia.

Authors:  H Mabuchi; J Koizumi; M Shimizu; R Takeda
Journal:  Circulation       Date:  1989-02       Impact factor: 29.690

3.  Estimated Prevalence of Heterozygous Familial Hypercholesterolemia in Patients With Acute Coronary Syndrome.

Authors:  Hirotoshi Ohmura; Yoshifumi Fukushima; Atsushi Mizuno; Koichiro Niwa; Yohei Kobayashi; Toshiaki Ebina; Kazuo Kimura; Shun Ishibashi; Hiroyuki Daida
Journal:  Int Heart J       Date:  2017-01-24       Impact factor: 1.862

4.  Prevalence of familial hypercholesterolemia in patients with acute coronary syndrome in Japan: Results of the EXPLORE-J study.

Authors:  Mariko Harada-Shiba; Junya Ako; Hidenori Arai; Atsushi Hirayama; Yoshitaka Murakami; Atsushi Nohara; Asuka Ozaki; Kiyoko Uno; Masato Nakamura
Journal:  Atherosclerosis       Date:  2018-10       Impact factor: 5.162

5.  Impact of LDLR and PCSK9 pathogenic variants in Japanese heterozygous familial hypercholesterolemia patients.

Authors:  Mika Hori; Naotaka Ohta; Atsushi Takahashi; Hiroaki Masuda; Rieko Isoda; Suguru Yamamoto; Cheol Son; Masatsune Ogura; Kiminori Hosoda; Yoshihiro Miyamoto; Mariko Harada-Shiba
Journal:  Atherosclerosis       Date:  2019-08-19       Impact factor: 5.162

6.  Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society.

Authors:  Børge G Nordestgaard; M John Chapman; Steve E Humphries; Henry N Ginsberg; Luis Masana; Olivier S Descamps; Olov Wiklund; Robert A Hegele; Frederick J Raal; Joep C Defesche; Albert Wiegman; Raul D Santos; Gerald F Watts; Klaus G Parhofer; G Kees Hovingh; Petri T Kovanen; Catherine Boileau; Maurizio Averna; Jan Borén; Eric Bruckert; Alberico L Catapano; Jan Albert Kuivenhoven; Päivi Pajukanta; Kausik Ray; Anton F H Stalenhoef; Erik Stroes; Marja-Riitta Taskinen; Anne Tybjærg-Hansen
Journal:  Eur Heart J       Date:  2013-08-15       Impact factor: 29.983

7.  Guidance for Pediatric Familial Hypercholesterolemia 2017.

Authors:  Mariko Harada-Shiba; Takao Ohta; Akira Ohtake; Masatsune Ogura; Kazushige Dobashi; Atsushi Nohara; Shizuya Yamashita; Koutaro Yokote
Journal:  J Atheroscler Thromb       Date:  2018-02-06       Impact factor: 4.928

8.  Application of the Japanese Guidelines for the Diagnosis of Familial Hypercholesterolemia in General Practice: It is to be Validated in International Harmonization.

Authors:  Nobukiyo Tanaka; Tomohiko Teramoto; Shinji Yokoyama
Journal:  J Atheroscler Thromb       Date:  2018-11-27       Impact factor: 4.928

9.  Universal Screening for Familial Hypercholesterolemia in Children in Kagawa, Japan.

Authors:  Keiji Matsunaga; Asako Mizobuchi; Hai Ying Fu; Shohei Ishikawa; Hayato Tada; Masa-Aki Kawashiri; Ichiro Yokota; Tsuyoshi Sasaki; Shigeru Ito; Jun Kunikata; Takashi Iwase; Tomohiro Hirao; Katsunori Yokoyama; Yoichi Hoshikawa; Takuji Fujisawa; Kazushige Dobashi; Takashi Kusaka; Tetsuo Minamino
Journal:  J Atheroscler Thromb       Date:  2021-06-26       Impact factor: 4.394
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.